In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection

PLoS Neglected Tropical Diseases

Volumn 5, Issue 6, 2011, Pages

  de Alwis, Ruklanthi ^a   Beltramello, Martina ^b   Messer, William B ^a   Sukupolvi Petty, Soila ^c   Wahala, Wahala M P B ^a   Kraus, Annette ^a   Olivarez, Nicholas P ^a   Pham, Quang ^a   Brian, James ^c   Tsai, Wen Yang ^d   Wang, Wei Kung ^d   Halstead, Scott ^e   Kliks, Srisakul ^e   Diamond, Michael S ^c   Baric, Ralph ^a   Lanzavecchia, Antonio ^b   Sallusto, Federica ^b   de Silva, Aravinda M ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Switzerland)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF HAWAII   (United States)

^e International Vaccine Institute   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; RECOMBINANT ANTIGEN; VIRUS ENVELOPE PROTEIN; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS ANTIGEN;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY COMBINING SITE; ANTIBODY DETECTION; ANTIBODY ISOLATION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CELL ASSAY; CONTROLLED STUDY; CROSS REACTION; DENGUE; DENGUE VIRUS; DISEASE SEVERITY; HUMAN; MEMORY CELL; NONHUMAN; PRIMARY INFECTION; SCREENING TEST; SEROTYPE; VIRUS NEUTRALIZATION; VIRUS PARTICLE; BLOOD; IMMUNOLOGY; TIME;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CROSS REACTIONS; DENGUE; DENGUE VIRUS; HUMANS; TIME FACTORS;

EID: 79959856684     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001188     Document Type: Article

References (43)

1. Roehrig JT, (2003) Antigenic structure of flavivirus proteins. Adv Virus Res 59: 141-175.
2. Halstead SB, (2002) Dengue. Curr Opin Infect Dis 15: 471-476.
3. Rothman AL, (2004) Dengue: defining protective versus pathologic immunity. J Clin Invest 113: 946-951.
4. Halstead SB, (2003) Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 60: 421-467.
5. Halstead SB, Marchette NJ, Sung Chow JS, Lolekha S, (1976) Dengue virus replication enhancement in peripheral blood leukocytes from immune human beings. Proc Soc Exp Biol Med 151: 136-139.
6. Halstead SB, Chow JS, Marchette NJ, (1973) Immunological enhancement of dengue virus replication. Nat New Biol 243: 24-26.
7. Goncalvez AP, Engle RE, St Claire M, Purcell RH, Lai CJ, (2007) Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Natl Acad Sci U S A 104: 9422-9427.
8. Balsitis SJ, Williams KL, Lachica R, Flores D, Kyle JL, et al. (2010) Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog 6: e1000790.
9. Zellweger RM, Prestwood TR, Shresta S, (2010) Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe 7: 128-139.
10. Pierson TC, Diamond MS, (2008) Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection. Expert Rev Mol Med 10: e12.
11. Pierson TC, Fremont DH, Kuhn RJ, Diamond MS, (2008) Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development. Cell Host Microbe 4: 229-238.
12. Modis Y, Ogata S, Clements D, Harrison SC, (2003) A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci U S A 100: 6986-6991.
13. Modis Y, Ogata S, Clements D, Harrison SC, (2005) Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein. J Virol 79: 1223-1231.
14. Nybakken GE, Nelson CA, Chen BR, Diamond MS, Fremont DH, (2006) Crystal structure of the West Nile virus envelope glycoprotein. J Virol 80: 11467-11474.
15. Rey FA, Heinz FX, Mandl C, Kunz C, Harrison SC, (1995) The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature 375: 291-298.
16. Crill WD, Roehrig JT, (2001) Monoclonal Antibodies That Bind to Domain III of Dengue Virus E Glycoprotein Are the Most Efficient Blockers of Virus Adsorption to Vero Cells J Virol 75: 7769-7773 10.1128/JVI.75.16.7769-7773.2001.
17. Gromowski GD, Barrett AD, (2007) Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology 366: 349-360.
18. Gromowski GD, Barrett ND, Barrett AD, (2008) Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus. J Virol 82: 8828-8837.
19. Lin B, Parrish CR, Murray JM, Wright PJ, (1994) Localization of a Neutralizing Epitope on the Envelope Protein of Dengue Virus Type 2. Virology 202: 885-890.
20. Lok SM, Kostyuchenko V, Nybakken GE, Holdaway HA, Battisti AJ, et al. (2008) Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat Struct Mol Biol 15: 312-317.
21. Roehrig JT, Bolin RA, Kelly RG, (1998) Monoclonal Antibody Mapping of the Envelope Glycoprotein of the Dengue 2 Virus, Jamaica. Virology 246: 317-328.
22. Sukupolvi-Petty S, Austin SK, Engle M, Brien JD, Dowd KA, et al. (2010) Structure and Function Analysis of Therapeutic Monoclonal Antibodies against Dengue Virus Type 2. J Virol.
23. Sukupolvi-Petty S, Austin SK, Purtha WE, Oliphant T, Nybakken GE, et al. (2007) Type- and Subcomplex-Specific Neutralizing Antibodies against Domain III of Dengue Virus Type 2 Envelope Protein Recognize Adjacent Epitopes J Virol 81: 12816-12826 10.1128/JVI.00432-07.
24. Shrestha B, Brien JD, Sukupolvi-Petty S, Austin SK, Edeling MA, et al. (2010) The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog 6: e1000823.
25. Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, et al. (2010) Cross-reacting antibodies enhance dengue virus infection in humans. Science 328: 745-748.
26. Schieffelin JS, Costin JM, Nicholson CO, Orgeron NM, Fontaine KA, et al. (2010) Neutralizing and non-neutralizing monoclonal antibodies against dengue virus E protein derived from a naturally infected patient. Virol J 7: 28.
27. Crill WD, Hughes HR, Delorey MJ, Chang GJ, (2009) Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens. PLoS ONE 4: e4991.
28. Lai CY, Tsai WY, Lin SR, Kao CL, Hu HP, et al. (2008) Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J Virol 82: 6631-6643.
29. Wahala WM, Kraus AA, Haymore LB, Accavitti-Loper MA, de Silva AM, (2009) Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology 392: 103-113.
30. Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, et al. (2010) The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8: 271-283.
31. Kraus AA, Messer W, Haymore LB, de Silva AM, (2007) Comparison of Plaque- and Flow Cytometry- Based Methods for Measuring Dengue Virus Neutralization. J Clin Microbiol 45: 3777-3780.
32. Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, et al. (2010) The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8: 271-283.
33. Oliphant T, Nybakken GE, Engle M, Xu Q, Nelson CA, et al. (2006) Antibody Recognition and Neutralization Determinants on Domains I and II of West Nile Virus Envelope Protein 10.1128/JVI.01732-06. J Virol 80: 12149-12159.
34. Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, et al. (2004) An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med 10: 871-875.
35. Mukhopadhyay S, Kuhn RJ, Rossmann MG, (2005) A structural perspective of the flavivirus life cycle. Nat Rev Microbiol 3: 13-22.
36. Vogt MR, Moesker B, Goudsmit J, Jongeneelen M, Austin SK, et al. (2009) Human monoclonal antibodies against West Nile virus induced by natural infection neutralize at a postattachment step. J Virol 83: 6494-6507.
37. Sanchez MD, Pierson TC, Degrace MM, Mattei LM, Hanna SL, et al. (2007) The neutralizing antibody response against West Nile virus in naturally infected horses. Virology 359: 336-348.
38. Oliphant T, Nybakken GE, Austin SK, Xu Q, Bramson J, et al. (2007) Induction of Epitope-Specific Neutralizing Antibodies against West Nile Virus 10.1128/JVI.00643-07. J Virol 81: 11828-11839.
39. Yu IM, Zhang W, Holdaway HA, Li L, Kostyuchenko VA, et al. (2008) Structure of the immature dengue virus at low pH primes proteolytic maturation. Science 319: 1834-1837.
40. Yu IM, Holdaway HA, Chipman PR, Kuhn RJ, Rossmann MG, et al. (2009) Association of the pr peptides with dengue virus at acidic pH blocks membrane fusion. J Virol 83: 12101-12107.
41. Cherrier MV, Kaufmann B, Nybakken GE, Lok SM, Warren JT, et al. (2009) Structural basis for the preferential recognition of immature flaviviruses by a fusion-loop antibody. Embo J 28: 3269-3276.
42. Nelson S, Jost CA, Xu Q, Ess J, Martin JE, et al. (2008) Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization. PLoS Pathog 4: e1000060.
43. Rodenhuis-Zybert IA, van der Schaar HM, da Silva Voorham JM, van der Ende-Metselaar H, Lei HY, et al. (2010) Immature dengue virus: a veiled pathogen? PLoS Pathog 6: e1000718.